NCT05554913View on ClinicalTrials.gov

Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 8, 2022

Primary Completion Date

February 20, 2024

Study Completion Date

February 20, 2024

Conditions

Chemotherapy-induced Thrombocytopenia

Interventions

DRUG

QL0911

This study is designed to study QL0911 for the treatment of chemotherapy-induced thrombocytopenia (CIT) in patients receiving chemotherapy for cancer

DRUG

Placebo

Placebo comparator

Trial Locations (1)

200120

Shanghai East Hospital, Shanghai

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT05554913 - Evaluating the Efficacy and Safety of QL0911 in the Prevention of Chemotherapy- Induced Thrombocytopenia | Biotech Hunter | Biotech Hunter